Evidence map›Paper›PMID 34444748›Full record

ArticleNutrients2021

Palmitoleoylethanolamide Is an Efficient Anti-Obesity Endogenous Compound: Comparison with Oleylethanolamide in Diet-Induced Obesity.

Rubén Tovar, Ana Luisa Gavito, Antonio Vargas, Laura Soverchia, Laura Hernandez-Folgado, Nadine Jagerovic, Elena Baixeras, Roberto Ciccocioppo, Fernando Rodríguez de Fonseca, Juan Decara

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05560971 (The Effect of Palmitoleic Acid), which is not on this map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05560971 naactive not recruitingnot on this mapstarted 2022, after this paper: background citation

The Effect of Palmitoleic Acid (POA) Supplementation on Insulin Sensitivity and Lipogenesis in Overweight and Obese Individuals

TypeinterventionalSponsorBrigham and Women's HospitalRan2022 to 2027Enrolled40ConditionsPreDiabetes, Insulin Resistance, Overweight, ObesityArmsPalmitoleic acid, Placebo
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Palmitoylethanolamide in Human and Animal Obesity.Molecules (Basel, Switzerland) · 2026
    Review
  4. Article
  5. Novel insights of ferroptosis in atherosclerosis progression.Frontiers in cell and developmental biology · 2026
    Review
  6. Review
  7. Article
  8. Endocannabinoid System and Metabolism: The Influences of Sex.International journal of molecular sciences · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Rubén TovarInstituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Regional de Málaga, UGC Salud Mental, Avda. Carlos Haya 82, Pabellón de Gobierno, 29010 Málaga, Spain.ORCID 0000-0002-4517-8932
Ana Luisa GavitoInstituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Regional de Málaga, UGC Salud Mental, Avda. Carlos Haya 82, Pabellón de Gobierno, 29010 Málaga, Spain.
Antonio VargasInstituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Regional de Málaga, UGC Salud Mental, Avda. Carlos Haya 82, Pabellón de Gobierno, 29010 Málaga, Spain.
Laura SoverchiaPharmacology Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, Italy.
Laura Hernandez-FolgadoInstituto de Química Médica, CSIC, C/Juan de la Cierva 3, 28006 Madrid, Spain.
Nadine JagerovicInstituto de Química Médica, CSIC, C/Juan de la Cierva 3, 28006 Madrid, Spain.ORCID 0000-0003-2642-6969
Elena BaixerasDepartamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Málaga, 29010 Málaga, Spain.
Roberto CiccocioppoPharmacology Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, Italy.ORCID 0000-0003-3126-9240
Fernando Rodríguez de FonsecaInstituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Regional de Málaga, UGC Salud Mental, Avda. Carlos Haya 82, Pabellón de Gobierno, 29010 Málaga, Spain.ORCID 0000-0002-4516-5795
Juan DecaraInstituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Regional de Málaga, UGC Salud Mental, Avda. Carlos Haya 82, Pabellón de Gobierno, 29010 Málaga, Spain.ORCID 0000-0002-9868-015X
Instituto de Investigación Biomédica de Málaga · ESUniversità di Camerino · ITInstituto de Química Médica · ESUniversidad de Málaga · ES

Funding

Consejería de Salud y Familias, Junta de Andalucía PI-0139-2018Instituto de Salud Carlos III PI19/01577Ministerio de Ciencia e Innovación DTS19/00125Ministerio de Economía, Industria y Competitividad, Gobierno de España 2019-007329-1Ministerio de Educación, Cultura y Deporte CAS15/00257
6 · The paper itself

Abstract

Obesity is currently a major epidemic in the developed world. However, we lack a wide range of effective pharmacological treatments and therapies against obesity, and those approved are not devoid of adverse effects. Dietary components such as palmitoleic acid have been proposed to improve metabolic disbalance in obesity, although the mechanisms involved are not well understood. Both palmitoleic acid (POA) and oleic acid (OA) can be transformed in N-acylethanolamines (NAEs), mediating the effects of dietary POA and OA. To test this hypothesis, here, we study the effects on food intake and body weight gain of palmitoleylethanolamide (POEA) and the OA-derived NAE analogue, oleoylethanolamide (OEA), in Sprague-Dawley rats with a hypercaloric cafeteria diet (HFD). Plasma biochemical metabolites, inflammatory mediators, and lipogenesis-associated liver protein expression were also measured. The results indicate that POEA is able to improve health status in diet-induced obesity, decreasing weight, liver steatosis, inflammation, and dyslipemia. The action of POEA was found to be almost identical to that of OEA, which is an activator of the nuclear peroxisome proliferator receptor alpha (PPARα), and it is structurally related to POEA. These results suggest that the dietary administration of either POA or POEA might be considered as nutritional intervention as complementary treatment for complicated obesity in humans.

Indexed as

AnimalsBody WeightCytokinesDietEndocannabinoidsEthanolaminesFatty AcidsFatty Acids, MonounsaturatedFatty LiverHumansInsulin ResistanceLipogenesisLiverMaleObesityOleic AcidCytokinesEndocannabinoidsEthanolaminesFatty AcidsFatty Acids, MonounsaturatedN-acylethanolaminesOleic AcidOleic AcidsoleoylethanolamideOleylethanolamidepalmitoleic acidcannabinoid receptors type 1hypercaloric cafeteria dietmonounsaturated fatty acidsN-acylethanolamineoleic acidoleylethanolamidepalmitoleic acidpalmitoleylethanolamideperoxisome proliferator receptor alpha

Identifiers

PMID34444748
PMCPMC8400335
OpenAlexW3183872978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.